Foundation

Knowledge transmission

Training and conferences

It’s for the same reason that the company intervened in Nantes in a cycle of conference to help in the development of the online visibility for charitable organisations.

Support

A long-time commitment is also in progress with a chacun son cap, the organisation is offering children, teenager and to young adults, affected or having been affected by leukemia or cancer, to take part in cruises on sailboats in Brittany.

Long-term support

First of all with Pas de Futur sans Numérique during which he capsized in the Minitransatlantic race 2013, then with Entreprise(s) Innovante(s) for the Transgascogne and the Minitransatlantic race 2015 and now with Griffon.fr.

With 7 races, of which he won 7, Ian is the favourite for the Mini of 2017.

Les filles à l'ouest

Sponsoring of one crew participating in this competition where only women are allowed to compete. The goal was to unite the various stages with a road-portfolio, of a map and of a compass.

It is about a race and about a united commitment. The participants begin the adventure in two people towards new territories and people.
Challenge, mutual aid but also meetings with the others is the purpose of this rally.

Patron of the Rennes 1 Foundation, particularly the Cancer and Innovation Chair & the Chair for Mobility in a Sustainable City.

The first project brings bioinformatics expertise to advance cancer research, while the second chair focuses on leveraging open data to enhance sustainable urban mobility. Concentrating on air quality and student commuting at the Beaulieu campus, the project aims to strengthen the Rennes ecosystem in these areas.

Patron of the Nantes University Foundation, specifically for the Childhood Cancers Chair.

At the Research Center in Oncology and Immunology of Nantes-Angers, a team led by Stéphane Birklé explores a significant breakthrough in pediatric cancer treatment, especially those of the nervous system. Their innovative approach, called T-CAR immunotherapy, utilizes the child's own T lymphocytes, modified by gene therapy, to target and eliminate cancer cells.